サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1563846

血液検査の世界市場

Blood Screening

出版日
ページ情報
英文 158 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
血液検査の世界市場
出版日: 2024年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 158 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血液検査の世界市場は2030年までに38億米ドルに達する見込み

2023年に26億米ドルと推定される血液検査の世界市場は、分析期間2023-2030年にCAGR 5.6%で成長し、2030年には38億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである核酸検査（NAT）は、CAGR 5.3％を記録し、分析期間終了までに17億米ドルに達すると予測されます。酵素結合免疫吸着測定法（ELISA）分野の成長率は、分析期間のCAGRで6.2％と推定されます。

米国市場は6億9,770万米ドルと推定、中国はCAGR 9.1％で成長すると予測

米国の血液検査市場は、2023年に6億9,770万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 9.1%で推移し、2030年には8億3,140万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と6.0%と予測されています。欧州では、ドイツがCAGR 3.0%で成長すると予測されています。

世界の血液検査市場- 主要動向と促進要因のまとめ

血液検査はなぜ安全なヘルスケアに不可欠なのか？

血液検査はヘルスケアにおける重要なプロセスであり、輸血、臓器移植、診断目的で使用される前に、血液サンプル中の感染因子、遺伝子疾患、その他の健康状態を検出するように設計されています。このスクリーニング・プロセスは、血液および血液製剤の安全性を確保し、HIV、肝炎、梅毒などの感染症を予防するために不可欠です。血液検査はまた、がんや遺伝性遺伝性疾患などの早期発見にも重要な役割を果たしており、タイムリーな介入と治療を可能にしています。血液スクリーニング検査の精度と信頼性は、患者の安全と公衆衛生に直接影響するため、最も重要です。安全な血液製剤への需要が世界的に高まり続ける中、血液検査は患者を守り、治療の有効性を保証する、現代ヘルスケアに不可欠な要素となっています。

テクノロジーの進化は、血液検査のプロセスをどのように変えたのでしょうか？

血液検査の分野は、テクノロジーの進歩により、より速く、より正確で、包括的な検査方法へと変貌を遂げました。従来、血液検査は手技と基本的な血清学的検査に頼っており、効果的ではありましたが、その範囲は限られており、結果が出るまでに数日かかることもありました。自動検査システムと分子診断学のイントロダクションは、血液検査のスピードと精度を飛躍的に向上させました。核酸検査（NAT）のような技術により、ウイルスや細菌の病原体をより早い段階で検出できるようになり、輸血による感染症のリスクを減らすことができます。さらに、ハイスループットスクリーニングシステムの開発により、大量の血液サンプルをより効率的に処理できるようになり、これは現代のヘルスケア施設の要求に応える上で極めて重要です。その結果、血液検査技術の進化は、血液製剤の安全性を高めるだけでなく、検出可能な疾患の範囲を拡大し、予防医療の要となっています。

血液検査技術の新たな動向とイノベーションとは？

血液検査は、より包括的で、より迅速で、費用対効果の高い診断ソリューションの必要性により、現在大きな技術革新が進行中です。最も注目すべき動向のひとつは、血液検査における次世代シーケンサー（NGS）の利用の拡大です。これにより、遺伝物質の詳細な分析が可能になり、1つの血液サンプルから幅広い病原体や遺伝性疾患を同定することができます。もう一つの新たな動向は、人工知能（AI）と機械学習を血液検査のプロセスに統合することで、従来の方法では見逃される可能性のあるパターンや異常を特定し、診断の精度を高めることです。さらに、ポイントオブケア（POC）検査機器の開発により、遠隔地や資源の限られた地域を含む様々な環境での迅速な検査が可能になり、重要な診断へのアクセスが改善されることで、血液検査は大きく変化しています。これらの技術革新は、血液検査で可能なことの限界を押し広げ、早期発見、より個別化された治療オプション、患者の転帰改善の可能性を提供しています。

血液検査市場の拡大を促進する要因は？

血液検査市場の成長は、ヘルスケアにおける安全で正確な診断の重要性の高まりを強調するいくつかの重要な要因によって牽引されています。主な促進要因の一つは、特にヘルスケアインフラが拡大しつつある新興市場における血液および血液製剤の需要増です。手術、輸血、移植の増加に伴い、感染症のトランスミッションを防止するための厳格な血液検査の必要性が緊急性を増しています。核酸検査（NAT）や次世代シークエンシング（NGS）の採用といった技術の進歩も、より正確で効率的なスクリーニング・オプションを提供することで市場の成長を後押ししています。さらに、慢性疾患の有病率の増加、早期発見と予防医療への関心の高まりが、包括的な血液スクリーニング検査の需要を押し上げています。政府のイニシアティブや規制に支えられた公衆衛生基準の向上に対する世界の後押しが、血液検査市場の拡大をさらに後押ししています。これらの要因は、診断技術における継続的な革新と相まって、現代ヘルスケアにおける血液検査の重要な役割を浮き彫りにし、世界中の患者の安全と幸福を保証しています。

調査対象企業の例（合計 12社）

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols International SA
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP10749

Global Blood Screening Market to Reach US$3.8 Billion by 2030

The global market for Blood Screening estimated at US$2.6 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Nucleic Acid Test (NAT), one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Enzyme-Linked Immunosorbent Assay (ELISA) segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$697.7 Million While China is Forecast to Grow at 9.1% CAGR

The Blood Screening market in the U.S. is estimated at US$697.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$831.4 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Blood Screening Market - Key Trends and Drivers Summarized

Why Is Blood Screening Essential in Ensuring Safe Healthcare Practices?

Blood screening is a critical process in healthcare, designed to detect infectious agents, genetic disorders, and other health conditions in blood samples before they are used for transfusions, organ transplants, or diagnostic purposes. This screening process is vital to ensuring that blood and blood products are safe for use, thereby preventing the transmission of diseases such as HIV, hepatitis, and syphilis. Blood screening also plays a crucial role in the early detection of conditions like cancer and inherited genetic disorders, allowing for timely intervention and treatment. The accuracy and reliability of blood screening tests are paramount, as they directly impact patient safety and public health. As the demand for safe blood products continues to rise globally, blood screening has become an indispensable component of modern healthcare, protecting patients and ensuring the efficacy of medical treatments.

How Has the Evolution of Technology Transformed Blood Screening Processes?

The field of blood screening has been revolutionized by advancements in technology, leading to faster, more accurate, and comprehensive testing methods. Traditionally, blood screening relied on manual techniques and basic serological tests, which, while effective, were limited in scope and could take days to yield results. The introduction of automated testing systems and molecular diagnostics has drastically improved the speed and accuracy of blood screening. Techniques such as nucleic acid testing (NAT) allow for the detection of viral and bacterial pathogens at a much earlier stage, reducing the risk of transmitting infections through blood transfusions. Additionally, the development of high-throughput screening systems has enabled the processing of large volumes of blood samples more efficiently, which is crucial in meeting the demands of modern healthcare facilities. As a result, the evolution of blood screening technology has not only enhanced the safety of blood products but has also expanded the range of detectable conditions, making it a cornerstone of preventive healthcare.

What Are the Emerging Trends and Innovations in Blood Screening Technology?

Blood screening is currently undergoing significant innovation, driven by the need for more comprehensive, faster, and cost-effective diagnostic solutions. One of the most notable trends is the growing use of next-generation sequencing (NGS) in blood screening, which allows for the detailed analysis of genetic material and the identification of a wide range of pathogens and genetic disorders from a single blood sample. Another emerging trend is the integration of artificial intelligence (AI) and machine learning into blood screening processes, which enhances the accuracy of diagnostics by identifying patterns and anomalies that might be missed by conventional methods. Furthermore, the development of point-of-care (POC) testing devices is transforming blood screening by enabling rapid testing in various settings, including remote and resource-limited areas, thus improving access to critical diagnostics. These innovations are pushing the boundaries of what is possible in blood screening, offering the potential for earlier detection, more personalized treatment options, and improved patient outcomes.

What Are the Factors Fueling Expansion of the Blood Screening Market?

The growth in the blood screening market is driven by several critical factors that underscore the increasing importance of safe and accurate diagnostics in healthcare. One of the primary drivers is the rising demand for blood and blood products, particularly in emerging markets where healthcare infrastructure is expanding. As more surgeries, transfusions, and transplants are performed, the need for rigorous blood screening to prevent the transmission of infectious diseases is becoming more urgent. Technological advancements, such as the adoption of nucleic acid testing (NAT) and next-generation sequencing (NGS), are also fueling market growth by offering more precise and efficient screening options. Additionally, the increasing prevalence of chronic diseases and the growing focus on early detection and preventive care are boosting the demand for comprehensive blood screening tests. The global push for improved public health standards, supported by government initiatives and regulations, is further driving the expansion of the blood screening market. These factors, combined with ongoing innovations in diagnostic technology, highlight the critical role of blood screening in modern healthcare, ensuring the safety and well-being of patients worldwide.

Select Competitors (Total 12 Featured) -

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols International SA
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Blood Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Safe Blood Donations Throws the Spotlight on Advanced Blood Screening Technologies
    • Increasing Incidence of Bloodborne Diseases Drives Demand for Comprehensive Blood Screening Tests
    • Advancements in Molecular Diagnostics Propel Growth in Rapid and Accurate Blood Screening Solutions
    • Shift Toward Early Disease Detection Expands Addressable Market Opportunity for Blood Screening Innovations
    • Innovations in High-Throughput Screening Accelerate Demand for Efficient Blood Testing Systems
    • Expansion of Point-of-Care Diagnostics Spurs Growth in Portable and Rapid Blood Screening Devices
    • Integration of AI in Diagnostics Drives Adoption of Automated Blood Screening Systems
    • Innovations in Sample Collection and Processing Are Enhancing Blood Screening Accuracy
    • Growing Importance of Infection Control Expands Market Penetration for Comprehensive Blood Screening Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blood Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nucleic Acid Test (NAT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Western Blot Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Blood Banks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • JAPAN
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • CHINA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • EUROPE
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • FRANCE
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • GERMANY
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • INDIA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • AFRICA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030

IV. COMPETITION